Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.

Childers WE Jr, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC 3rd, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD.

J Med Chem. 2010 May 27;53(10):4066-84. doi: 10.1021/jm1000908.

PMID:
20443629
2.

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.

J Pharmacol Exp Ther. 2007 Jan;320(1):486-96. Epub 2006 Oct 12.

PMID:
17038512
3.

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.

Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S.

J Pharmacol Exp Ther. 2005 May;313(2):862-9. Epub 2005 Feb 10.

PMID:
15705738
4.

Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor.

Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, Rosenzweig-Lipson S, Harrison B.

Bioorg Med Chem Lett. 2004 May 17;14(10):2603-7.

PMID:
15109661
5.

1,2,5-Thiadiazole derivatives are potent and selective ligands at human 5-HT1A receptors.

Sabb AL, Vogel RL, Kelly MG, Palmer Y, Smith DL, Andree TH, Schechter LE.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1069-71.

PMID:
11327592
6.

Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines.

Welmaker GS, Nelson JA, Sabalski JE, Sabb AL, Potoski JR, Graziano D, Kagan M, Coupet J, Dunlop J, Mazandarani H, Rosenzweig-Lipson S, Sukoff S, Zhang Y.

Bioorg Med Chem Lett. 2000 Sep 4;10(17):1991-4.

PMID:
10987434
7.

The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.

Bartolomeo AC, Morris H, Buccafusco JJ, Kille N, Rosenzweig-Lipson S, Husbands MG, Sabb AL, Abou-Gharbia M, Moyer JA, Boast CA.

J Pharmacol Exp Ther. 2000 Feb;292(2):584-96.

PMID:
10640295
8.

Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.

Sabb AL, Husbands GM, Tokolics J, Stein RP, Tasse RP, Boast CA, Moyer JA, Abou-Gharbia M.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):1895-900.

PMID:
10450949

Supplemental Content

Support Center